Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer - Reply

被引：1
|
作者：
Buzdar, AU [1 ]
Theriault, RL [1 ]
Hunt, KK [1 ]
Hortobagyi, GN [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 30期
关键词：
D O I：
10.1200/JCO.2005.03.2797
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：7760 / 7761
页数：2
相关论文
共 50 条
  • [41] Paclitaxel, carboplatin, and trastuzumab in HER2-positive metastatic breast cancer
    Andrew D. Seidman
    Larry Norton
    Current Oncology Reports, 2005, 7 (1) : 9 - 11
  • [42] Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis
    Ma, Wenhua
    Zhao, Fugang
    Zhou, Changpeng
    Zhang, Yongqian
    Zhao, Yingchun
    Li, Na
    Xie, Peng
    ONCOTARGETS AND THERAPY, 2019, 12 : 379 - 390
  • [43] Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
    Sardesai, Sagar
    Sukumar, Jasmine
    Kassem, Mahmoud
    Palettas, Marilly
    Stephens, Julie
    Morgan, Evan
    Addison, Daniel
    Baliga, Ragavendra
    Stover, Daniel G.
    VanDeusen, Jeffrey
    Williams, Nicole
    Cherian, Mathew
    Lustberg, Maryam
    Wesolowski, Robert
    Ramaswamy, Bhuvaneswari
    CARDIO-ONCOLOGY, 2020, 6 (01)
  • [44] A Phase II Preoperative Trial of Concurrent Trastuzumab and Paclitaxel without Anthracycline in HER2-Positive Operable Breast Cancer
    Sato, T.
    Hayashida, T.
    Takahashi, M.
    Sakata, M.
    Jinno, H.
    Hirose, S.
    Mukai, M.
    Kitagawa, Y.
    CANCER RESEARCH, 2010, 70
  • [45] Adjuvant Trastuzumab in HER2-Positive Breast Cancer REPLY
    Slamon, Dennis J.
    Buyse, Marc
    Press, Michael F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07): : 663 - 665
  • [46] Predictive factors of resistance to trastuzumab as neoadjuvant therapy in women with HER2-positive breast cancer
    Jinno, Hiromitsu
    Sato, Tomomi
    Takahashi, Maiko
    Hayashida, Tetsu
    Hirose, Shigemichi
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [47] Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
    Ricciardi, Giuseppina Rosaria Rita
    Franchina, Tindara
    Russo, Alessandro
    Schifano, Silvia
    Ferraro, Giuseppa
    Adamo, Vincenzo
    ONCOTARGETS AND THERAPY, 2016, 9 : 4351 - 4355
  • [48] Efficacy and tolerability of neoadjuvant Pertuzumab, Trastuzumab, and weekly Paclitaxel in Locally advanced Her-2 positive Breast cancer
    Gupta, Niraj
    Giblin, Erica
    Spivey, Tara
    Govert, Kristen
    Leagre, Christopher
    Liebross, Robert
    Tumati, Vasu
    Dugan, Thomas
    Yadav, Rina
    Henman, Patrick
    Beaudrie, Nick
    Bair, Tessa
    Durk, Jessica
    Hancock, Marjaorie
    Engle, Trisha
    Myers, Michelle
    Schneiders, Julie
    Tigges, Thomas
    CANCER RESEARCH, 2021, 81 (04)
  • [49] Prevalence of Cardiotoxicity Secondary to Trastuzumab in Patients with HER-2-Positive Breast Cancer in Southeast Mexico
    Pascual-Mathey, Luz I.
    Velez-Figueroa, Midory I.
    Diaz-Vallejo, Joel J.
    Mendez-Hirata, Gustavo
    Mendez-Machado, Gustavo F.
    REPORTS, 2024, 7 (03)
  • [50] The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment
    Lin, Mengmeng
    Xiong, Weiping
    Wang, Shiyuan
    Li, Yingying
    Hou, Chunying
    Li, Chunyu
    Li, Guohui
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 8
12345